ArticleJournal of thoracic disease2026
Prevalence and outcomes of pleuroparenchymal fibroelastosis in patients with non-tuberculous mycobacterial pulmonary disease: a French retrospective cohort study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pleuroparenchymal fibroelastosis (PPFE) is a recently described interstitial lung disease associated with multiple diseases. Japanese studies found an association between PPFE and non-tuberculous mycobacterial pulmonary disease (NTM-PD), but no study has been conducted in Europe. We aimed to assess in France the prevalence of PPFE among patients with NTM-PD, and to look for risk factors of PPFE and mortality. Method: We conducted a retrospective cohort study in two French hospitals from January 1, 2020 to March 31, 2022. NTM-PD patients were included if they had at least one chest high-resolution computed tomography (HRCT) scan available, to identify the presence or the occurrence of radiological patterns of PPFE based on established criteria. Risk factors for PPFE and five-year mortality were assessed using univariate and multivariate analyses. Results: A total of 101 patients were included, PPFE was identified in 14 patients (13.9%) and was associated with a lower body mass index (BMI) at diagnosis [odds ratio (OR) 21.4, 95% confidence interval (CI): 3.5-415.3 for BMI <18 kg/m² with PPFE, P<0.001] in multivariate exploratory analysis. Seventy patients had a minimum of two chest HRCT scans spaced by at least 3 years. Among them, 10 had PPFE: 8 at NTM-PD diagnosis, and 1 PPFE developing from pleural caps 9 years later. Five-year mortality could be studied for 71 patients. PPFE was associated with 5-year mortality (OR 6.3, 95% CI: 1.3-29.9, P=0.02) in multivariate exploratory analysis. Conclusions: PPFE is frequently observed among patients with NTM-PD, and seems to be associated with a lower BMI and the 5-year mortality, supporting its systematic screening in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.